Archive - GLP-1 Observer

The GLP-1 Lilly Isn’t Aiming at Obesity

Week Of July 4 – July 10, 2026

Jul 10 • Michael Parker, MD

A Semaglutide Patch and an Amycretin Bet

Week Of June 27 - July 3, 2026

Jul 3 • Michael Parker, MD

June 2026

China’s Triple Hits Phase 3, Lilly Bridges Medicare

Week Of June 20 – June 26, 2026

Jun 26 • Michael Parker, MD

Structure Takes the Next Step, Novo’s Pill Pulls Ahead

Week Of June 13 - June 19, 2026

Jun 19 • Michael Parker, MD

ADA’s Big Week, Lilly and AstraZeneca Among the Headlines

Week Of June 6 - June 12, 2026

Jun 12 • Michael Parker, MD

China’s Incretin Wave, ADA on Deck

Week Of May 30 - June 5, 2026

Jun 5 • Michael Parker, MD

May 2026

Foundayo Coverage and Dual-Agonist Liver Updates

Week Of May 23 - May 29, 2026

May 29 • Michael Parker, MD

Retatrutide’s Results, Wegovy Gears Up For Europe

Week Of May 16 – May 22, 2026

May 22 • Michael Parker, MD

Maintenance Trials and Drug Responders

Week Of May 9 – May 15, 2026

May 15 • Michael Parker, MD

Combos, CagriSema, and Heart Failure

Week Of May 2 – May 8, 2026

May 8 • Michael Parker, MD

Survodutide’s Number, Foundayo’s Bias

Week Of April 25 – May 1, 2026

May 1 • Michael Parker, MD

April 2026

Sites, Selectivity, and Petrelintide Positioning

Week Of April 18 – April 24, 2026

Apr 24 • Michael Parker, MD

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts